Relapsed Peripheral T-Cell Lymphoma

Oncology
2
Pipeline Programs
2
Companies
18
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
1
AlisertibPhase 3Small Molecule5 trials
Active Trials
NCT02560025Completed42Est. Dec 2018
NCT02259010Completed24Est. Oct 2016
NCT02214147Completed36Est. Jul 2016
+2 more trials
Acrotech Biopharma
Acrotech BiopharmaNJ - East Windsor
1 program
1
Folotyn and LeucovorinPhase 21 trial
Active Trials
NCT02106650CompletedEst. Jun 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaAlisertib
TakedaAlisertib
Acrotech BiopharmaFolotyn and Leucovorin
TakedaAlisertib
TakedaAlisertib
TakedaAlisertib
TakedaAlisertib
TakedaAlisertib
TakedaAlisertib
TakedaAlisertib
TakedaAlisertib
TakedaAlisertib
TakedaAlisertib
TakedaAlisertib
TakedaAlisertib

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 1,083 patients across 18 trials

NCT01482962TakedaAlisertib

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Start: Jun 2012Est. completion: Dec 2017271 patients
Phase 3Completed
NCT02560025TakedaAlisertib

Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML

Start: Dec 2015Est. completion: Dec 201842 patients
Phase 2Completed
NCT02106650Acrotech BiopharmaFolotyn and Leucovorin

Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies

Start: Jul 2014Est. completion: Jun 2019
Phase 2Completed
NCT01091428TakedaAlisertib

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Start: Apr 2010Est. completion: Jul 2017191 patients
Phase 2Completed
NCT00853307TakedaAlisertib

MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Start: Mar 2009Est. completion: Jan 201131 patients
Phase 2Completed
NCT00830518TakedaAlisertib

A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome

Start: Feb 2009Est. completion: Jul 201157 patients
Phase 2Completed
NCT01848067TakedaAlisertib

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Start: Aug 2013Est. completion: Jun 20169 patients
Phase 1/2Completed
NCT01397825TakedaAlisertib

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

Start: Aug 2011Est. completion: Oct 201645 patients
Phase 1/2Completed
NCT02259010TakedaAlisertib

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Start: Oct 2014Est. completion: Oct 201624 patients
Phase 1Completed
NCT02214147TakedaAlisertib

Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function

Start: Aug 2014Est. completion: Jul 201636 patients
Phase 1Completed
NCT01924260TakedaAlisertib

Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer

Start: Aug 2013Est. completion: Feb 201726 patients
Phase 1Completed
NCT01844583TakedaAlisertib

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

Start: Jun 2013Est. completion: Sep 201655 patients
Phase 1Completed
NCT01714947TakedaAlisertib

Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib

Start: Jan 2013Est. completion: Jun 20133 patients
Phase 1Completed
NCT01512758TakedaAlisertib

A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas

Start: Feb 2012Est. completion: Oct 201336 patients
Phase 1Completed
NCT00962091TakedaAlisertib

Study of MLN8237 in Participants With Advanced Solid Tumors

Start: Sep 2009Est. completion: Jul 201453 patients
Phase 1Completed
NCT00697346TakedaAlisertib

Study of MLN8237 in Participants With Advanced Hematological Malignancies

Start: Jul 2008Est. completion: Oct 201658 patients
Phase 1Completed
NCT00651664TakedaAlisertib

A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies

Start: Oct 2007Est. completion: Apr 201159 patients
Phase 1Completed
NCT00500903TakedaAlisertib

A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

Start: May 2007Est. completion: Feb 201187 patients
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)